- Lung cancer therapy including novel compounds and early phase trials
- Breast cancer therapeutics including novel compounds and early phase trials
- Health services research
- Economics of lung cancer therapy
- Treatment decision-making in advanced cancer, including development of patient decision aids
- Patient-physician communication
The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective.
Cancer Cytopathol. 2018 Dec 04;:
Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.
Oncologist. 2018 Nov 26;:
Curr Oncol. 2018 Oct;25(5):e385-e390
Nature. 2018 Nov 14;:
Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.
Lung Cancer. 2018 Nov;125:1-7
Curr Drug Targets. 2018 Sep 10;:
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol. 2018 Aug 28;:JCO2018783118
Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk.
Nat Commun. 2018 Aug 13;9(1):3221
BMC Med Genomics. 2018 Aug 09;11(1):65
The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Lung Cancer. 2018 Sep;123:22-29
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
President, Lung Cancer Canada
Chair, Working Group on Economic Analysis, National Cancer Institute of Canada Clinical Trials Group